Upcoming Webinars

Navigating from target identification to validation can be a complex process, so it makes sense to find the right assays and models to validate or refute a hypothesis ahead of spending vast amounts of money on clinical trials. CRISPR-Cas gene editing has made an impact in this space with forward genetic screens being seen as […]

Covid-19 has highlighted the current operational vulnerabilities in pharmaceutical research and in the drug discovery pipeline. Bringing new drugs to the market is still a slow and expensive process, with far too high costs, failure rates and cycle times. With low reproducibility and inefficient processes delaying the path to approval, the pandemic is prompting a […]

Effective preclinical assessment of drug safety and efficacy is essential to help reduce the risk of drug-induced toxicity and late-stage drug attrition. Current preclinical tests for safety depend on in vivo testing in higher-order species to achieve translational accuracy; however, animal models are expensive and do not adequately recapitulate human physiology due to species differences. […]

Immune checkpoints are signalling molecules that control the synapse between T cells and antigen presenting cells (APCs). Checkpoint inhibitor therapies target and inhibit the signals that ‘switch off’ T cells, leading to an upregulation of T cell activation and tumour cell killing.  The mixed lymphocyte reaction (MLR) mimics the T cell and APC synapse by […]

In vitro early stage compound profiling often focusses on single timepoint measurements of drug action, for example the affinity of the drug for its target at equilibrium, or the endpoint response in a signalling assay. However, in vivo, drug action occurs within a highly dynamic system. Drug and competing messenger concentrations at the site of […]

This webinar looks at T cell exhaustion. This is recognised as a major challenge in the development of immuno-oncology therapies. Used to describe the loss of effector function due to chronic antigen exposure, it commonly occurs within the tumour microenvironment. This impairs the T cells’ ability to effectively eradicate cancerous cells. The development of tumour […]

The Kinetics of Drug-Receptor Binding: Why it is important and how we can measure it? Sponsored by BMGLabtech & CISBio Optimizing the receptor binding kinetics of new drugs can have significant benefits, ranging from improved duration of action to enhanced efficacy through the insurmountable antagonism of dynamic physiological systems. Despite this, the kinetics of new […]